<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35275912</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle.</ArticleTitle>
        <Pagination>
          <StartPage>e0259807</StartPage>
          <MedlinePgn>e0259807</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0259807</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0259807</ELocationID>
        <Abstract>
          <AbstractText>Francisella tularensis is the etiologic agent of tularemia and a Tier I Select Agent. Subspecies tularensis (Type A) is the most virulent of the four subspecies and inhalation of as few as 10 cells can cause severe disease in humans. Due to its niche as a facultative intracellular pathogen, a successful tularemia vaccine must induce a robust cellular immune response, which is best achieved by a live, attenuated strain. F. tularensis strains lacking lipopolysaccharide (LPS) O-antigen are highly attenuated, but do not persist in the host long enough to induce protective immunity. Increasing the persistence of an O-antigen mutant may help stimulate protective immunity. Alginate encapsulation is frequently used with probiotics to increase persistence of bacteria within the gastrointestinal system, and was used to encapsulate the highly attenuated LVS O-antigen mutant WbtIG191V. Encapsulation with alginate followed by a poly-L-lysine/alginate coating increased survival of WbtIG191V in complement-active serum. In addition, BALB/c mice immunized intraperitoneally with encapsulated WbtIG191V combined with purified LPS survived longer than mock-immunized mice following intranasal challenge. Alginate encapsulation of the bacteria also increased antibody titers compared to non-encapsulated bacteria. These data suggest that alginate encapsulation provides a slow-release vehicle for bacterial deposits, as evidenced by the increased antibody titer and increased persistence in serum compared to freely suspended cells. Survival of mice against high-dose intranasal challenge with the LVS wildtype was similar between mice immunized within alginate capsules or with LVS, possibly due to the low number of animals used, but bacterial loads in the liver and spleen were the lowest in mice immunized with WbtIG191V and LPS in beads. However, an analysis of the immune response of surviving mice indicated that those vaccinated with the alginate vehicle upregulated cell-mediated immune pathways to a lesser extent than LVS-vaccinated mice. In summary, this vehicle, as formulated, may be more effective for pathogens that require predominately antibody-mediated immunity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Freudenberger Catanzaro</LastName>
            <ForeName>Kelly C</ForeName>
            <Initials>KC</Initials>
            <Identifier Source="ORCID">0000-0002-7500-3914</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lahmers</LastName>
            <ForeName>Kevin K</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Allen</LastName>
            <ForeName>Irving C</ForeName>
            <Initials>IC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inzana</LastName>
            <ForeName>Thomas J</ForeName>
            <Initials>TJ</Initials>
            <Identifier Source="ORCID">0000-0002-5769-5902</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, United States of America.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Veterinary Medicine, Long Island University, Brookville, New York, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000464">Alginates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001428">Bacterial Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019081">O Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000464" MajorTopicYN="N">Alginates</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001428" MajorTopicYN="N">Bacterial Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005604" MajorTopicYN="Y">Francisella tularensis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019081" MajorTopicYN="N">O Antigens</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014406" MajorTopicYN="Y">Tularemia</DescriptorName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>17</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35275912</ArticleId>
        <ArticleId IdType="pmc">PMC8916679</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0259807</ArticleId>
        <ArticleId IdType="pii">PONE-D-21-33517</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Services CfDCaPaDoHaH. Possession, Use, and Transfer of Select Agents and Toxins; Biennial review; Final Rule. 2012. p. 61083–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23038847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.. Tularemia as a biological weapon: medical and public health management. JAMA: the journal of the American Medical Association. 2001;285(21):2763–73. doi: 10.1001/jama.285.21.2763 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.285.21.2763</ArticleId>
            <ArticleId IdType="pubmed">11386933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia Q, Horwitz MA. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis. Front Cell Infect Microbiol. 2018;8(154). doi: 10.3389/fcimb.2018.00154
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2018.00154</ArticleId>
            <ArticleId IdType="pmc">PMC5963219</ArticleId>
            <ArticleId IdType="pubmed">29868510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tigertt WD. Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev. 1962;26:354–73. Epub 1962/09/01. doi: 10.1128/br.26.3.354-373.1962
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/br.26.3.354-373.1962</ArticleId>
            <ArticleId IdType="pmc">PMC441156</ArticleId>
            <ArticleId IdType="pubmed">13985026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Archives of internal medicine. 1961;107:689–701. doi: 10.1001/archinte.1961.03620050055006 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.1961.03620050055006</ArticleId>
            <ArticleId IdType="pubmed">13746668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961;107:702–14. doi: 10.1001/archinte.1961.03620050068007 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.1961.03620050068007</ArticleId>
            <ArticleId IdType="pubmed">13746667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961;87:415–25. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13889609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hood AM. Virulence factors of Francisella tularensis. J Hyg (Lond). 1977;79(1):47–60. Epub 1977/08/01. doi: 10.1017/s0022172400052840
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/s0022172400052840</ArticleId>
            <ArticleId IdType="pmc">PMC2129918</ArticleId>
            <ArticleId IdType="pubmed">267668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandstrom G, Lofgren S, Tarnvik A. A Capsule-Deficient Mutant of Francisella-Tularensis Lvs Exhibits Enhanced Sensitivity to Killing by Serum but Diminished Sensitivity to Killing by Polymorphonuclear Leukocytes. Infect Immun. 1988;56(5):1194–202. doi: 10.1128/iai.56.5.1194-1202.1988
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.56.5.1194-1202.1988</ArticleId>
            <ArticleId IdType="pmc">PMC259783</ArticleId>
            <ArticleId IdType="pubmed">3356465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorokin VM, Pavlovich NV, Prozorova LA. Francisella tularensis resistance to bactericidal action of normal human serum. FEMS Immunol Med Microbiol. 1996;13(3):249–52. doi: 10.1111/j.1574-695X.1996.tb00246.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-695X.1996.tb00246.x</ArticleId>
            <ArticleId IdType="pubmed">8861038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlan JW, Shen H, Webb A, Perry MB. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine. 2002;20(29–30):3465–71. doi: 10.1016/s0264-410x(02)00345-6 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0264-410x(02)00345-6</ArticleId>
            <ArticleId IdType="pubmed">12297391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartley G, Taylor R, Prior J, Newstead S, Hitchen PG, Morris HR, et al.. Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice. Vaccine. 2006;24(7):989–96. doi: 10.1016/j.vaccine.2005.08.075 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2005.08.075</ArticleId>
            <ArticleId IdType="pubmed">16257097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raynaud C, Meibom KL, Lety MA, Dubail I, Candela T, Frapy E, et al.. Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect Immun. 2007;75(1):536–41. doi: 10.1128/IAI.01429-06 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01429-06</ArticleId>
            <ArticleId IdType="pmc">PMC1828372</ArticleId>
            <ArticleId IdType="pubmed">17030571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, et al.. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology. 2007;153(Pt 9):3141–53. doi: 10.1099/mic.0.2007/006460-0 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/mic.0.2007/006460-0</ArticleId>
            <ArticleId IdType="pubmed">17768257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen JA, Post DM, Gibson BW, Lindemann SR, Apicella MA, Meyerholz DK, et al.. Francisella tularensis Schu S4 lipopolysaccharide core sugar and O-antigen mutants are attenuated in a mouse model of tularemia. Infect Immun. 2014;82(4):1523–39. doi: 10.1128/IAI.01640-13
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01640-13</ArticleId>
            <ArticleId IdType="pmc">PMC3993386</ArticleId>
            <ArticleId IdType="pubmed">24452684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Twine SM, Vinogradov E, Lindgren H, Sjostedt A, Conlan JW. Roles for wbtC, wbtI, and kdtA Genes in Lipopolysaccharide Biosynthesis, Protein Glycosylation, Virulence, and Immunogenicity in Francisella tularensis Strain SCHU S4. Pathogens. 2012;1(1):12–29. Epub 2012/09/10. doi: 10.3390/pathogens1010012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pathogens1010012</ArticleId>
            <ArticleId IdType="pmc">PMC4141488</ArticleId>
            <ArticleId IdType="pubmed">25152813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappellano G, Abreu H, Casale C, Dianzani U, Chiocchetti A. Nano-Microparticle Platforms in Developing Next-Generation Vaccines. Vaccines (Basel). 2021;9(6). Epub 2021/07/03. doi: 10.3390/vaccines9060606
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines9060606</ArticleId>
            <ArticleId IdType="pmc">PMC8228777</ArticleId>
            <ArticleId IdType="pubmed">34198865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kailasapathy K.
Microencapsulation of probiotic bacteria: technology and potential applications. Current issues in intestinal microbiology. 2002;3(2):39–48. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12400637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popovic M, Stojanovic M, Velickovic Z, Kovacevic A, Miljkovic R, Mirkovic N, et al.. Characterization of potential probiotic strain, L. reuteri B2, and its microencapsulation using alginate-based biopolymers. Int J Biol Macromol. 2021;183:423–34. Epub 2021/05/02. doi: 10.1016/j.ijbiomac.2021.04.177 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2021.04.177</ArticleId>
            <ArticleId IdType="pubmed">33932415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ta LP, Bujna E, Antal O, Ladanyi M, Juhasz R, Szecsi A, et al.. Effects of various polysaccharides (alginate, carrageenan, gums, chitosan) and their combination with prebiotic saccharides (resistant starch, lactosucrose, lactulose) on the encapsulation of probiotic bacteria Lactobacillus casei 01 strain. Int J Biol Macromol. 2021;183:1136–44. Epub 2021/05/02. doi: 10.1016/j.ijbiomac.2021.04.170 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2021.04.170</ArticleId>
            <ArticleId IdType="pubmed">33932423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam MA, Yun CH, Choi YJ, Cho CS. Microencapsulation of live probiotic bacteria. Journal of microbiology and biotechnology. 2010;20(10):1367–77. doi: 10.4014/jmb.1003.03020 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4014/jmb.1003.03020</ArticleId>
            <ArticleId IdType="pubmed">21030820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sultana K, Godward G, Reynolds N, Arumugaswamy R, Peiris P, Kailasapathy K. Encapsulation of probiotic bacteria with alginate-starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt. Int J Food Microbiol. 2000;62(1–2):47–55. Epub 2001/01/04. doi: 10.1016/s0168-1605(00)00380-9 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0168-1605(00)00380-9</ArticleId>
            <ArticleId IdType="pubmed">11139021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandramouli V, Kailasapathy K, Peiris P, Jones M. An improved method of microencapsulation and its evaluation to protect Lactobacillus spp. in simulated gastric conditions. J Microbiol Methods. 2004;56(1):27–35. Epub 2004/01/07. doi: 10.1016/j.mimet.2003.09.002 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mimet.2003.09.002</ArticleId>
            <ArticleId IdType="pubmed">14706748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding WK, Shah NP. An improved method of microencapsulation of probiotic bacteria for their stability in acidic and bile conditions during storage. Journal of food science. 2009;74(2):M53–61. doi: 10.1111/j.1750-3841.2008.01030.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1750-3841.2008.01030.x</ArticleId>
            <ArticleId IdType="pubmed">19323758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun. 2008;76(6):2448–55. doi: 10.1128/IAI.00767-07
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00767-07</ArticleId>
            <ArticleId IdType="pmc">PMC2423109</ArticleId>
            <ArticleId IdType="pubmed">18362129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Kahl-McDonagh M, Wong-Gonzalez A, et al.. Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J Wildl Dis. 2009;45(4):1021–9. doi: 10.7589/0090-3558-45.4.1021 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7589/0090-3558-45.4.1021</ArticleId>
            <ArticleId IdType="pubmed">19901378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. J Wildl Dis. 2009;45(1):165–73. doi: 10.7589/0090-3558-45.1.165
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7589/0090-3558-45.1.165</ArticleId>
            <ArticleId IdType="pmc">PMC3350799</ArticleId>
            <ArticleId IdType="pubmed">19204345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dezfuly ZT, Alishahi M, Ghorbanpoor M, Tabandeh MR, Mesbah M. Immunogenicity and protective efficacy of Yersinia ruckeri lipopolysaccharide (LPS), encapsulated by alginate-chitosan micro/nanoparticles in rainbow trout (Oncorhyncus mykiss). Fish Shellfish Immunol. 2020;104:25–35. Epub 2020/05/31. doi: 10.1016/j.fsi.2020.05.029 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2020.05.029</ArticleId>
            <ArticleId IdType="pubmed">32473361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sotomayor-Gerding D, Troncoso JM, Pino A, Almendras F, Diaz MR. Assessing the Immune Response of Atlantic Salmon (Salmo salar) after the Oral Intake of Alginate-Encapsulated Piscirickettsia salmonis Antigens. Vaccines (Basel). 2020;8(3). Epub 2020/08/17. doi: 10.3390/vaccines8030450
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines8030450</ArticleId>
            <ArticleId IdType="pmc">PMC7565443</ArticleId>
            <ArticleId IdType="pubmed">32796725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dounighi NM, Shahcheraghi F, Razzaghi-Abyaneh M, Nofeli M, Zolfagharian H. A New Vaccine Delivery Vehicle and Adjuvant Candidate: Bordetella pertussis Inactivated Whole Cells Entrapped in Alginate Microspheres. Curr Pharm Des. 2017;23(18):2665–72. Epub 2017/01/13. doi: 10.2174/1381612823666170112124303 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612823666170112124303</ArticleId>
            <ArticleId IdType="pubmed">28079006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, et al.. Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis. 2007;196(1):134–7. Epub 2007/06/01. doi: 10.1086/518611 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/518611</ArticleId>
            <ArticleId IdType="pubmed">17538893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, et al.. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine. 2008;26(41):5276–88. Epub 2008/08/12. doi: 10.1016/j.vaccine.2008.07.051
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2008.07.051</ArticleId>
            <ArticleId IdType="pmc">PMC2652725</ArticleId>
            <ArticleId IdType="pubmed">18692537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cimolai N, Taylor GP, Mah D, Morrison BJ. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol Immunol. 1992;36(5):465–78. Epub 1992/01/01. doi: 10.1111/j.1348-0421.1992.tb02045.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1348-0421.1992.tb02045.x</ArticleId>
            <ArticleId IdType="pubmed">1513263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchi. Operation Manual Encapsulator B-395 Pro. p. 61–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Conlan JW, Chen W, Shen H, Webb A, KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog. 2003;34(5):239–48. Epub 2003/05/07. doi: 10.1016/s0882-4010(03)00046-9 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0882-4010(03)00046-9</ArticleId>
            <ArticleId IdType="pubmed">12732472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandara AB, Champion AE, Wang X, Berg G, Apicella MA, McLendon M, et al.. Isolation and mutagenesis of a capsule-like complex (CLC) from Francisella tularensis, and contribution of the CLC to F. tularensis virulence in mice. PloS one. 2011;6(4):e19003. doi: 10.1371/journal.pone.0019003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0019003</ArticleId>
            <ArticleId IdType="pmc">PMC3081320</ArticleId>
            <ArticleId IdType="pubmed">21544194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlan JW, Chen W, Bosio CM, Cowley SC, Elkins KL. Infection of mice with Francisella as an immunological model. Curr Protoc Immunol. 2011;Chapter 19:Unit 19 4. doi: 10.1002/0471142735.im1914s93
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/0471142735.im1914s93</ArticleId>
            <ArticleId IdType="pmc">PMC3405980</ArticleId>
            <ArticleId IdType="pubmed">21462168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlan JW. Vaccines against Francisella tularensis—past, present and future. Expert Rev Vaccines. 2004;3(3):307–14. Epub 2004/06/05. doi: 10.1586/14760584.3.3.307 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.3.3.307</ArticleId>
            <ArticleId IdType="pubmed">15176947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rohmer L, Brittnacher M, Svensson K, Buckley D, Haugen E, Zhou Y, et al.. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infect Immun. 2006;74(12):6895–906. doi: 10.1128/IAI.01006-06
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01006-06</ArticleId>
            <ArticleId IdType="pmc">PMC1698093</ArticleId>
            <ArticleId IdType="pubmed">17000723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wayne Conlan J, Oyston PC. Vaccines against Francisella tularensis. Annals of the New York Academy of Sciences. 2007;1105:325–50. doi: 10.1196/annals.1409.012 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1409.012</ArticleId>
            <ArticleId IdType="pubmed">17395730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobbs BE, Matson CA, Theofilou VI, Webb TJ, Younis RH, Barry EM. Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia. Pathogens. 2021;10(7). Epub 2021/07/03. doi: 10.3390/pathogens10070799
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pathogens10070799</ArticleId>
            <ArticleId IdType="pmc">PMC8308642</ArticleId>
            <ArticleId IdType="pubmed">34202420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlan JW, Sjostedt A, Gelhaus HC, Fleming P, McRae K, Cobb RR, et al.. Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 ΔclpB, to Prevent Tularemia. Pathogens. 2021;10(7). Epub 2021/07/03. doi: 10.3390/pathogens10070795
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/pathogens10070795</ArticleId>
            <ArticleId IdType="pmc">PMC8308573</ArticleId>
            <ArticleId IdType="pubmed">34201577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, et al.. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun. 2007;75(5):2591–602. Epub 2007/02/14. doi: 10.1128/IAI.01789-06
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01789-06</ArticleId>
            <ArticleId IdType="pmc">PMC1865767</ArticleId>
            <ArticleId IdType="pubmed">17296751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin CY, Zhao J, Llewellyn AC, Golovliov I, Sjostedt A, Zhou P, et al.. Francisella FlmX broadly affects lipopolysaccharide modification and virulence. Cell Rep. 2021;35(11):109247. Epub 2021/06/17. doi: 10.1016/j.celrep.2021.109247 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109247</ArticleId>
            <ArticleId IdType="pubmed">34133919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The Brucella abortus S19 ΔvjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun. 2009;77(2):877–84. doi: 10.1128/IAI.01017-08
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01017-08</ArticleId>
            <ArticleId IdType="pmc">PMC2632017</ArticleId>
            <ArticleId IdType="pubmed">19047401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa LF, Cabello AL, Batista DFA, Chaki SP, de Figueiredo P, da Paixao TA, et al.. The candidate vaccine strain Brucella ovis abcBA is protective against Brucella melitensis infection in mice. Microbiol Immunol. 2020;64(11):730–6. Epub 2020/09/24. doi: 10.1111/1348-0421.12850 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1348-0421.12850</ArticleId>
            <ArticleId IdType="pubmed">32965738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, Huang Y, Zheng C, Dong S, Liang W. Alginate-chitosan-PLGA composite microspheres enabling single-shot hepatitis B vaccination. AAPS J. 2010;12(4):519–24. Epub 2010/06/26. doi: 10.1208/s12248-010-9213-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1208/s12248-010-9213-1</ArticleId>
            <ArticleId IdType="pmc">PMC2977004</ArticleId>
            <ArticleId IdType="pubmed">20577912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, et al.. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A. 2009;106(11):4343–8. Epub 2009/03/03. doi: 10.1073/pnas.0813411106
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0813411106</ArticleId>
            <ArticleId IdType="pmc">PMC2657382</ArticleId>
            <ArticleId IdType="pubmed">19251656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun. 2007;75(5):2152–62. doi: 10.1128/IAI.01606-06
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01606-06</ArticleId>
            <ArticleId IdType="pmc">PMC1865787</ArticleId>
            <ArticleId IdType="pubmed">17296747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mara-Koosham G, Hutt JA, Lyons CR, Wu TH. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun. 2011;79(4):1770–8. Epub 2011/02/02. doi: 10.1128/IAI.00605-10
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00605-10</ArticleId>
            <ArticleId IdType="pmc">PMC3067570</ArticleId>
            <ArticleId IdType="pubmed">21282410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna O, Larson JC, Moya ML, Opara EC, Brey EM. Generation of alginate microspheres for biomedical applications. Journal of visualized experiments: JoVE. 2012;(66). doi: 10.3791/3388 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/3388</ArticleId>
            <ArticleId IdType="pmc">PMC3481983</ArticleId>
            <ArticleId IdType="pubmed">22907205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Post DMB, Slutter B, Schilling B, Chande AT, Rasmussen JA, Jones BD, et al.. Characterization of Inner and Outer Membrane Proteins from Francisella tularensis Strains LVS and Schu S4 and Identification of Potential Subunit Vaccine Candidates. MBio. 2017;8(5). Epub 2017/10/12. doi: 10.1128/mBio.01592-17
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.01592-17</ArticleId>
            <ArticleId IdType="pmc">PMC5635693</ArticleId>
            <ArticleId IdType="pubmed">29018123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stenmark S, Lindgren H, Tarnvik A, Sjostedt A. Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog. 2003;35(2):73–80. doi: 10.1016/s0882-4010(03)00095-0 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0882-4010(03)00095-0</ArticleId>
            <ArticleId IdType="pubmed">12901846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ajdary S, Dobakhti F, Taghikhani M, Riazi-Rad F, Rafiei S, Rafiee-Tehrani M. Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine. 2007;25(23):4595–601. Epub 2007/05/15. doi: 10.1016/j.vaccine.2007.03.039 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2007.03.039</ArticleId>
            <ArticleId IdType="pubmed">17498857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowley SC, Sedgwick JD, Elkins KL. Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. Journal of immunology. 2007;179(11):7709–19. Epub 2007/11/21. doi: 10.4049/jimmunol.179.11.7709 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.11.7709</ArticleId>
            <ArticleId IdType="pubmed">18025217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL. Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. Journal of immunology. 2010;184(10):5791–801. Epub 2010/04/16. doi: 10.4049/jimmunol.1000362 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1000362</ArticleId>
            <ArticleId IdType="pubmed">20393138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, et al.. Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect. 2011;13(3):261–75. Epub 2010/11/13. doi: 10.1016/j.micinf.2010.10.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micinf.2010.10.022</ArticleId>
            <ArticleId IdType="pmc">PMC3031720</ArticleId>
            <ArticleId IdType="pubmed">21070859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelava I, Mihelcic M, Ozanic M, Marecic V, Knezevic M, Curlin M, et al.. Atg5-Deficient Mice Infected with Francisella tularensis LVS Demonstrate Increased Survival and Less Severe Pathology in Internal Organs. Microorganisms. 2020;8(10). Epub 2020/10/11. doi: 10.3390/microorganisms8101531
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/microorganisms8101531</ArticleId>
            <ArticleId IdType="pmc">PMC7600933</ArticleId>
            <ArticleId IdType="pubmed">33036147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plzakova L, Kubelkova K, Krocova Z, Zarybnicka L, Sinkorova Z, Macela A. B cell subsets are activated and produce cytokines during early phases of Francisella tularensis LVS infection. Microb Pathog. 2014;75:49–58. Epub 2014/09/10. doi: 10.1016/j.micpath.2014.08.009 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micpath.2014.08.009</ArticleId>
            <ArticleId IdType="pubmed">25200734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plzakova L, Krocova Z, Kubelkova K, Macela A. Entry of Francisella tularensis into Murine B Cells: The Role of B Cell Receptors and Complement Receptors. PloS one. 2015;10(7):e0132571. Epub 2015/07/15. doi: 10.1371/journal.pone.0132571
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0132571</ArticleId>
            <ArticleId IdType="pmc">PMC4498600</ArticleId>
            <ArticleId IdType="pubmed">26161475</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
